CompuGroup Medical SE

  • WKN: 543730
  • ISIN: DE0005437305
  • Land: Deutschland

Nachricht vom 14.10.2019 | 10:49

CompuGroup Medical SE: Release of a capital market information

CompuGroup Medical SE / Share Buyback

14.10.2019 / 10:49
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


CompuGroup Medical SE: Disclosure pursuant to Art. 5 Para. 1 lit. b) and Para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Para. 2 and Para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 4th Interim Announcement

CompuGroup Medical SE / Share Buyback

 

Koblenz, October 14, 2019

CompuGroup Medical SE: Disclosure pursuant to Art. 5 Para. 1 lit. b) and Para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Para. 2 and Para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 4th Interim Announcement

In the period from October 7, 2019, up to and including October 11, 2019, CompuGroup Medical SE has bought back a total of 59,854 shares of CompuGroup Medical SE within the framework of the share buyback program. In the announcement of September 17, 2019, pursuant to Art. 2 para. 1 of the Commission Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 (MAR) it was communicated that the repurchase of treasury shares would commence on September 18, 2019.

The overall volume of the shares bought back daily in the period from October 7, 2019, up to and including October 11, 2019, and the daily volume-weighted average stock market prices of the shares are as follows:

Date Overall volume of shares bought back (number) Volume-weighted average stock market price
(EUR, excluding ancillary costs of purchase, rounded to four places according to commercial practice)
October 7, 2019 11,371 53.3709
October 8, 2019 10,790 52.9795
October 9, 2019 15,425 52.6950
October 10, 2019 13,268 52.3901
October 11, 2019 9,000 53.6019
     
In total: 59,854 52.9435
 

The total number of shares which have been bought back so far by CompuGroup Medical SE since September 18, 2019, up to and including October 11, 2019, within the framework of the share buyback program thus amounts to 260,689 no-par value shares.

Further information pursuant to Art. 5 para. 1 lit. b) and para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 para. 2 and para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 is available online under https://www.cgm.com/sbb.

The purchase of the shares of CompuGroup Medical SE was carried out by a bank assigned by CompuGroup Medical SE and exclusively via the Frankfurt Stock Exchange (Xetra trading).

Koblenz, October 14, 2019

The Management Board

CompuGroup Medical SE
Investor Relations
Maria Trost 21
56070 Koblenz, Germany
T: 49 (0) 261 8000-6200
F: 49 (0) 261 8000-3200



14.10.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Henkel AG & Co. KGaA: Henkel bestätigt Ausblick für das Geschäftsjahr 2019

14. November 2019, 07:30

Aktueller Webcast

EQS Group AG

Conference Call zu den Neunmonatszahlen 2019

15. November 2019

Aktuelle Research-Studie

Uzin Utz AG

Original-Research: Uzin Utz AG (von Montega AG): Kaufen

15. November 2019